Dash Acquisitions Inc. Johnson & Johnson (NYSE:JNJ) Stock Position Decreases

Dash Acquisitions Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,786 shares of the company’s stock after selling 144 shares during the quarter. Dash Acquisitions Inc.’s holdings in Johnson & Johnson were worth $259,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently purchased and sold shares of the company. Kennedy Capital Management LLC increased its stake in shares of Johnson & Johnson by 18.6% during the 3rd quarter. Kennedy Capital Management LLC now owns 20,478 shares of the company’s stock valued at $3,189,000 after buying an additional 3,206 shares during the last quarter. Rainsberger Wealth Advisors Inc. boosted its stake in shares of Johnson & Johnson by 2.6% during the 3rd quarter. Rainsberger Wealth Advisors Inc. now owns 14,584 shares of the company’s stock valued at $2,271,000 after buying an additional 373 shares during the last quarter. Industrial Alliance Investment Management Inc. boosted its stake in shares of Johnson & Johnson by 125.4% during the 3rd quarter. Industrial Alliance Investment Management Inc. now owns 6,671 shares of the company’s stock valued at $1,039,000 after buying an additional 3,711 shares during the last quarter. Annandale Capital LLC increased its stake in shares of Johnson & Johnson by 6.8% during the 3rd quarter. Annandale Capital LLC now owns 19,171 shares of the company’s stock valued at $2,986,000 after buying an additional 1,221 shares during the last quarter. Finally, Dana Investment Advisors Inc. boosted its stake in shares of Johnson & Johnson by 125.4% during the 3rd quarter. Dana Investment Advisors Inc. now owns 106,403 shares of the company’s stock valued at $16,572,000 after buying an additional 59,199 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ stock opened at $145.62 on Thursday. The stock has a 50-day simple moving average of $148.02 and a 200-day simple moving average of $153.91. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The stock has a market capitalization of $350.46 billion, a P/E ratio of 9.08, a P/E/G ratio of 2.43 and a beta of 0.52. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter last year, the business posted $2.68 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. On average, sell-side analysts expect that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Wall Street Analysts Forecast Growth

Several research firms issued reports on JNJ. Morgan Stanley dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Bank of America dropped its price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday. Finally, The Goldman Sachs Group began coverage on Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target on the stock. Eight analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $174.07.

Get Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases containing HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.